Clinical Trial Update: GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for GT90001 plus nivolumab in advanced hepatocellular carcinoma (HCC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• GT90001
• nivolumab (nivolumab)

Snippet

Sponsor: Suzhou Kintor Pharmaceutical Inc, | Conditions: Hepatocellular Carcinoma, HCC | Phase 2 | Status: UNKNOWN